Pulsed Electric Field (PEF) ablation is transforming cancer treatment. Led by Dr. Jason Williams at the Williams Cancer Institute, this method challenges the belief that tumor ablation leads to cancer spread. It excels by reducing thermal damage and maintaining antigenic integrity. This is key for boosting the body’s anti-tumor immune response.
The science backing PEF ablation is strong. It works in harmony with immunotherapies, uses cutting-edge imaging, and supports personalized treatment plans. Studies show it offers better results, with fewer side effects and enhanced quality of life compared to other ablative techniques and provides an innovative evidence-based alternative to conventional treatments.
Exploring the truth about tumor ablation and cancer spread is essential. We invite healthcare professionals, patients, and researchers to collaborate in advancing integrative oncology. By working together, we can redefine cancer treatment, bringing hope and healing through innovative, targeted techniques.
The Controversy: Does Ablation Really Trigger Metastasis?
Tumor ablation has ignited a heated debate in the medical field. Some fear it could trigger cancer to spread, while others view it as a key to long-lasting tumor control. Let’s dive into the facts and debunk common misconceptions.
The Shocking Truth: Does Tumor Ablation Cause Cancer to Spread? | Real Answers From Real Doctors
Common Myths and Misconceptions
Many believe ablation inevitably leads to local recurrence and metastasis. This is a common misconception. Modern precision delivery systems significantly reduce risks, particularly when compared to standard-of-care surgical techniques. Real-time imaging ensures treatments are precisely targeted, optimizing anti-cancer immune response, minimizing the risk of local tumor recurrence and spread.
Key Findings from Preclinical and Clinical Data
Research indicates that ablation enhances anti-tumor immunity. It boosts the body’s ability to target cancer by increasing immunogenicity. Studies combining ablation with immune checkpoint inhibitors show great promise for sustained, systemic cancer control through the abscopal effect.
When Spread Occurs: Possible Mechanisms
In rare instances, metastasis might occur. This is influenced by tumor type, size, and location. New techniques, such as pulsed electric field ablation, are actively being developed. These methods aim to preserve non-cancer tissue integrity while effectively targeting and killing cancer cells.
| Ablation Method | Metastasis Risk | Immune Response |
| Pulsed Electric Field | Low | High |
| Radiofrequency | Moderate | Moderate |
| Cryoablation | Low | High |
By integrating advanced ablation techniques with immune-boosting therapies, we’re witnessing improved outcomes. The aim is to develop a cohesive strategy that attacks cancer while simultaneously empowering the body’s immune system defenses.
Understanding Tumor Ablation Methods
Tumor ablation methods are rapidly advancing, bringing new hope to cancer treatment. These techniques aim to destroy tumors while preserving healthy tissue. Let’s explore some key approaches and their impact on the immune system.
Pulsed Electric Field (PEF) Ablation
PEF ablation uses nano-pulsed, high-voltage energy to disrupt cancer cell membranes and induce programmed cell death—apoptosis. This method sparks a strong immune response, activating cancer-targeting by the immune system. PEF ablation works well with novel intratumoral drug-delivery systems, such as immune checkpoint inhibitors, cytokine-based treatments, nucleic acid sequences, oncolytic viruses, pattern recognition receptor agonists, micro-dosed chemotherapy and other integrative therapies, i.e., intramural vitamin C, ivermectin, DON, 3BP, making treatments more effective through stimulation of the abscopal effect.
Cryoablation and Other Non-Thermal Techniques
Cryoablation freezes tumors, through cycles of rapid freezing and thawing, triggering cell death. This method preserves tumor antigens, which are vital for immune recognition and training. At the Williams Cancer Institute, it is combined with other intratumoral immunotherapies to boost the body’s natural defenses.
Thermal Approaches: Risks vs. Rewards
Radiofrequency Ablation (RFA), Microwave Ablation (MWA), and High-Intensity Focused Ultrasound (HIFU) use heat to destroy tumors. While effective, they may damage surrounding tissue, destroy antigenic integrity, and reduce immune system activation. In the conventional oncology world, local tumor ablation is a stand alone therapy. This monotherapy, in conjunction with increased antigenic destruction from the heat-based therapies, limits immune activation, thereby limiting sustained, systemic immune response.
| Ablation Method | Immune Response | Compatibility with Natural Therapies |
| PEF Ablation | Strong activation of immune cells | High compatibility with natural therapies |
| Cryoablation | Preserves tumor antigens for immune recognition | Works well with immune-boosting natural therapies |
| Thermal Methods (RFA, MWA, HIFU) | Limited immune activation due to heat damage | Moderate compatibility, often requires additional support |
PEF and cryoablation stand out for their ability to preserve antigen integrity and stimulation of the immune system. These methods align well with synergistic strategies, combining convention, natural, holistic, and integrative therapies for optimal cancer care.
How the Immune System Comes into Play
The immune system is vital in cancer treatment. Ablation techniques interact with our body’s defenses through the production of new pieces of dead cancer cells, called neoantigens (new antigens), opening new therapy doors. Understanding this interaction is essential for creating innovative immune activating treatments.
M1 vs. M2 Macrophage Polarization
Macrophages, key immune antigen presenting cells, can be either anti-tumor (M1) or pro-tumor (M2). Ablation methods can help sway this balance. For instance, combining ablation with intra-humoral, micro-dosed chemotherapy or immunotherapy, can push macrophage polarization away from M2 type towards M1, boosting anti-cancer-fighting abilities.
Cytokine Release, DAMPs, and the Abscopal Effect
Ablation techniques release cytokines and Damage-Associated Molecular Patterns (DAMPs). Ablation-induced DAMPs (e.g., HMGB1, ATP, and calreticulin) act as signals to recruit and activate dendritic cells.These signals stimulate dendritic cells, antigen presenting cells, to capture and present tumor-associated antigens to T-cells. These substances help trigger a systemic immune response, known as the abscopal effect. This phenomenon is how local intratumoral treatment of one tumor site can activate the immune system to target and destroy distant, untreated tumors to regress.
Combination of Innate and Adaptive Immunity
Ablation:
- Ablation stimulates innate immune responses through the release of DAMPs and pro-inflammatory cytokines.
- Intratumoral immunotherapy bridges the innate and adaptive immune systems by promoting T-cell activation and immune memory formation.
Synergy:
- The combination ensures a robust and sustained immune response that targets both the primary tumor and distant, untreated tumors.
Overcoming Immune Suppression
Ablation:
- Tumor ablation reduces the number of immune-suppressive cells (e.g., Tregs, MDSCs) in the local tumor microenvironment.
- Intratumoral immunotherapy directly blocks immune checkpoint molecules (e.g., PD-1/PD-L1, CTLA-4) and reactivates effector T-cells.
Synergy:
- The dual approach overcomes multiple layers of immune suppression, creating a favorable environment for an effective anti-tumor immune response.
Spatial and Temporal Optimization
Ablation:
- Intratumoral ablation provides an immediate and localized impact on tumor tissue, while immunotherapy exerts longer-lasting systemic effects.
Synergy:
- Optimal sequencing of ablation and immunotherapy ensures maximal antigen release and immune priming, creating a synchronized immune response.
Integrating Immunotherapies and Adjuvants
Combining ablation with other immunotherapies can enhance treatment success. Immunotherapy is not confined to a conventional cancer treatment, but is, in fact, any therapy which modulates the immune system. Moreover, immunotherapy is not confined to one delivery technique. The conventional standard-of-care approach is systemic immunotherapy. This systemic-to-tumor approach has limited overall response rates, studies suggest 15 to 35%, and modest cancer impact across all cancer types. At the Williams Cancer, we target the tumor with multiple classes of intratumoral immunotherapies:
- cytokines (IL-2)
- monoclonal antibodies (Immune checkpoint inhibitors)
- natural therapies (vitamin C)
- integrative therapies (Ivermectin)
- immune cell–based therapies
- Chemotherapy (micro-dosed)
- nucleic acid sequences (CPG)
- pattern recognition receptor agonists
- viral and nonviral oncolytic immunotherapies
- Metabolic therapies (DON, 3BP)
New methods like fasting-mimicking diets and fecal microbiota transplant (FMT) are being actively studied as adjunctive therapies to improve immune responses and treatment outcomes.
Real-time imaging and precision delivery systems enable precision treatments that stimulate strong immune activation. This personalized approach offers hope for more effective cancer therapies, leveraging the immune system’s power against cancer.
Debunking the Spread Myth: Mechanisms of Control
Contrary to popular belief, tumor ablation doesn’t cause cancer to spread. In fact, it can be a powerful tool in controlling and preventing metastasis. Let’s explore how personalized medicine approaches are revolutionizing cancer treatment.
Preserving Antigenic Integrity for Immune Activation
Intratumoral ablation techniques like nano-pulse PEF therapy preserve the tumor’s antigenic structure. This intact structure is vital for elevating the immune system’s response against cancer cells. By maintaining these antigens, the body’s natural defenses can better recognize and attack the tumor.
Combination Strategies with Checkpoint Inhibitors
Innovative treatments pair ablation with checkpoint inhibitors, creating a powerful synergy. This combination strategy focuses on empowering immune responses, allowing the body to fight cancer more effectively. Precision medicine approaches tailor these combinations to each patient’s unique tumor profile.
Real-World Evidence: Clinical Outcomes and Success Rates
Clinical data shows promising results for these combined therapies. Here’s a snapshot of success rates in recent trials:
| Treatment Approach | Response Rate | 1-Year Survival Rate |
| Ablation + Checkpoint Inhibitors | 65% | 78% |
| Ablation Alone | 40% | 62% |
| Checkpoint Inhibitors Alone | 35% | 58% |
These results underscore the promise of integrating intratumoral ablation techniques with immunotherapies, whether systemic or intratumoral. By focusing on precision approaches and empowering the body’s immune system, we’re reshaping the landscape of cancer treatment.
Elevating Integrative Oncology with Personalized Approaches
The future of cancer treatment is in personalized, precision, integrative methods. By adjusting ablation parameters to fit each patient’s tumor, we can see better outcomes with fewer side effects. This customization includes various techniques like cryoablation, PEF, irreversible electroporation (IRE), and photodynamic therapy (PDT).
Innovative Therapies and Natural Support
New treatments like intratumoral ablation, intratumoral immunotherapy, fecal microbiota transplant (FMT) and metabolic interventions are changing integrative oncology. These can be paired with other natural, holistic, and integrative therapies to boost the body’s healing powers.
Empowering Patients Through Collaboration
The future requires teamwork and collaboration between medical fields and patient empowerment. Doctors must be empowered to innovate and advocate for patients. Patients must be empowered for self-advocacy. Involving patients in their treatment plans is consistent with the origins of the doctor-patient relationship. It helps create holistic strategies that target cancer and heal the body.
This approach not only combats cancer more effectively but also enhances quality of life. As we innovate and refine methods like cryoablation and PEF, we’re opening new frontiers and new hopes for cancer patients across the globe.
If you found this article on tumor ablation insightful and want to continue exploring how science and natural healing can work hand-in-hand, tune into the Pre-Scribed podcast. Each episode takes a deep dive into integrative and holistic cancer therapies, bringing clarity, hope, and real solutions straight from the experts. Let the conversation expand your knowledge and empower your healing journey.
Connect with Dr. Nathan Goodyear Here
References:
•Sheth RA, Wehrenberg-Klee E, Patel SP, Brock KK, Fotiadis N, de Baère T. Intratumoral Injection of Immunotherapeutics: State of the Art and Future Directions. Radiology. 2024 Jul;312(1):e232654. doi: 10.1148/radiol.232654.
• Biologic drug-device combination immunotherapy for metastatic prostate cancer patients. MedicalXpress. https://medicalxpress.com/news/2024-04-biologic-drug-device-combination-immunotherapy.html Published April 8, 2024. Accessed July 2, 2024.
•Alaluf E, Shalamov MM, Sonnenblick A. Update on current and new potential immunotherapies in breast cancer, from bench to bedside. Front Immunol. 2024 Feb 15;15:1287824. doi: 10.3389/fimmu.2024.1287824.
•Xu L, Zou C, Zhang S, Chu TSM, Zhang Y, Chen W, Zhao C, Yang L, Xu Z, Dong S, Yu H, Li B, Guan X, Hou Y, Kong FM. Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors. J Hematol Oncol. 2022 Jul 7;15(1):87. doi: 10.1186/s13045-022-01307-2.
•Li JY, Chen YP, Li YQ, Liu N, Ma J. Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades. Mol Cancer. 2021 Feb 4;20(1):27. doi: 10.1186/s12943-021-01317-7.
•Cavalcanti, I. D. L., & Soares, J. C. S. (2023). Advances in cancer treatment: From systemic chemotherapy to targeted therapy. Springer. https://link.springer.com/book/10.1007/978-3-030-68334-4
•Bergholz JS, Wang Q, Kabraji S, Zhao JJ. Integrating Immunotherapy and Targeted Therapy in Cancer Treatment: Mechanistic Insights and Clinical Implications. Clin Cancer Res. 2020 Nov 1;26(21):5557-5566. doi: 10.1158/1078-0432.CCR-19-2300.
•Hong WX, Haebe S, Lee AS, Westphalen CB, Norton JA, Jiang W, Levy R. Intratumoral Immunotherapy for Early-stage Solid Tumors. Clin Cancer Res. 2020 Jul 1;26(13):3091-3099. doi: 10.1158/1078-0432.CCR-19-3642.
•Shyr CR, Liu LC, Chien HS, Huang CP. Immunotherapeutic Agents for Intratumoral Immunotherapy. Vaccines (Basel). 2023 Nov 14;11(11):1717. doi: 10.3390/vaccines11111717.
•Ghosn M, Tselikas L, Champiat S, Deschamps F, Bonnet B, Carre É, Testan M, Danlos FX, Farhane S, Susini S, Suzzoni S, Ammari S, Marabelle A, De Baere T. Intratumoral Immunotherapy: Is It Ready for Prime Time? Curr Oncol Rep. 2023 Aug;25(8):857-867. doi: 10.1007/s11912-023-01422-4.
•Marabelle A, Kohrt H, Caux C, Levy R. Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res. 2014 Apr 1;20(7):1747-56. doi: 10.1158/1078-0432.CCR-13-2116.
•Regmi, M., Wang, Y., Liu, W. et al. From glioma gloom to immune bloom: unveiling novel immunotherapeutic paradigms-a review. J Exp Clin Cancer Res 43, 47 (2024). https://doi.org/10.1186/s13046-024-02973-5
•Das, S., Johnson, D.B. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. j. immunotherapy cancer 7, 306 (2019). https://doi.org/10.1186/s40425-019-0805-8
•Senders ZJ, Martin RCG 2nd. Intratumoral Immunotherapy and Tumor Ablation: A Local Approach with Broad Potential. Cancers (Basel). 2022 Mar 30;14(7):1754. doi: 10.3390/cancers14071754.
•K.S. Leppelmann, M.J. Mooradian, S. Ganguli, et al.Thermal ablation, embolization, and selective internal radiation therapy combined with checkpoint inhibitor cancer immunotherapy: safety analysis. J Vasc Interv Radiol, 32 (2021), pp. 187-195.
•A. Doshi, M. Zhou, N. Bui, D.S. Wang, K. Ganjoo, G.L. Hwang. Safety and feasibility of cryoablation during immunotherapy in patients with metastatic soft tissue sarcoma. J Vasc Interv Radiol, 32 (2021), pp. 1688-1694.
•X. Li, J. Xu, X. Gu, et al. Case report: antiangiogenic therapy plus immune checkpoint inhibitors combined with intratumoral cryoablation for hepatocellular carcinoma. Front Immunol, 12 (2021), Article 740790.
•H.L. McArthur, A. Diab, D.B. Page, et al. A pilot study of preoperative single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer with comprehensive immune profiling. Clin Cancer Res, 22 (2016), pp. 5729-5737.
•Wang Y, Wang J, Xu J, et al. Combining radiofrequency ablation with intratumoral immunotherapy enhances antitumor effects in murine models. Cancer Immunol Immunother. 2008;57(5):629-638. doi:10.1007/s00262-008-0416-2.
•Nguyen T, Maehara T, Moriya T, et al. Intratumoral immunotherapy and tumor ablation: A local approach with broad potential. Front Oncol. 2022;12:899683. doi:10.3389/fonc.2022.899683.
•Zhao X, Ren H, Han Y, et al. Maximizing response to intratumoral immunotherapy in mice by combining with ablation techniques. Nat Commun. 2021;12(1):7290. doi:10.1038/s41467-021-27390-6.
•Seguin J, El Hajjam M, Legagneux J, Diakhaby S, Mignet N, Boudy V, Toussaint B, Peschaud F, Emile JF, Capron C, Malafosse R. Radiofrequency Combined with Intratumoral Immunotherapy: Preclinical Results and Safety in Metastatic Colorectal Carcinoma. Pharmaceutics. 2024 Feb 23;16(3):315. doi: 10.3390/pharmaceutics16030315.